Back to top
more

Agilon Health (AGL)

(Delayed Data from NYSE)

$1.70 USD

1.70
3,042,453

-0.09 (-5.03%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $1.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alignment Healthcare (ALHC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +200.00% and +5.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Moumi Mondal headshot

CVS Health Care Delivery: Will the Growth Momentum Last in Q2?

by Moumi Mondal

CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.

Zacks Equity Research

Agilon Health (AGL) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of 100% and 1.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Zacks Equity Research

Sotera Health Company (SHC) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Sotera Health (SHC) delivered earnings and revenue surprises of 16.67% and 3.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

by Zacks Equity Research

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Zacks Equity Research

Agilon (AGL) Moves 26.1% Higher: Will This Strength Last?

by Zacks Equity Research

Agilon (AGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Agilon Health (AGL) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

Zacks Equity Research

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Agilon Health (AGL) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Zacks Equity Research

Agilon (AGL) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Agilon (AGL) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of -13.64% and 0.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for January 28th

by Zacks Equity Research

AGL, ASHTY and CCOZY have been added to the Zacks Rank #5 (Strong Sell) List on January 28, 2024.

Zacks Equity Research

New Strong Sell Stocks for January 24th

by Zacks Equity Research

WMS, AGL and EADSY have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2025.

Zacks Equity Research

New Strong Sell Stocks for January 21st

by Zacks Equity Research

VLVLY, AGL and APOG have been added to the Zacks Rank #5 (Strong Sell) List on January 21, 2025.

Zacks Equity Research

New Strong Sell Stocks for January 15th

by Zacks Equity Research

SKFRY, AGL and ADRZY have been added to the Zacks Rank #5 (Strong Sell) List on January 15, 2025.

Zacks Equity Research

New Strong Sell Stocks for January 10th

by Zacks Equity Research

AGL, AEO and AROC have been added to the Zacks Rank #5 (Strong Sell) List on January 10, 2024.

Zacks Equity Research

New Strong Sell Stocks for December 31st

by Zacks Equity Research

AGL, AMPH and CR have been added to the Zacks Rank #24 (Strong Sell) List on December 31, 2024.

Zacks Equity Research

New Strong Sell Stocks for December 13th

by Zacks Equity Research

AGL, BKGFY and BERY have been added to the Zacks Rank #5 (Strong Sell) List on December 13, 2024.

Zacks Equity Research

New Strong Sell Stocks for December 4th

by Zacks Equity Research

ATI, ARLP and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 4, 2024.

Zacks Equity Research

New Strong Sell Stocks for December 2nd

by Zacks Equity Research

ATI, ATS and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2024.

Zacks Equity Research

New Strong Sell Stocks for November 19th

by Zacks Equity Research

AGL, AFLYY and BATRK have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2024.

Zacks Equity Research

New Strong Sell Stocks for November 13th

by Zacks Equity Research

AOS, AGL and ABG have been added to the Zacks Rank #5 (Strong Sell) List on November 13, 2024.

Zacks Equity Research

Here's What Key Metrics Tell Us About Agilon (AGL) Q3 Earnings

by Zacks Equity Research

Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Agilon Health (AGL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of -190% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Elevance Health (ELV) Q3 Earnings Lag Estimates

by Zacks Equity Research

Elevance Health (ELV) delivered earnings and revenue surprises of -13.71% and 3.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?